Vext ScienceVEXTF -0.55%69 Gross Margin % is 45.42% as of Mar. 2026, which is 2% above its 10-year median of 44.45. GuruFocus rates VEXTF with a GF Score™ of 69/100 and a GF Value™ of $1.08 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 938 Drug Manufacturers companies, Vext Science ranks worse than 75.59% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Vext Science had a gross margin of 45.42% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Vext Science Gross Margin % Related Terms
Vext Science Gross Margin % Historical Data
* Premium members only.
The historical data trend for Vext Science's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Vext Science's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Vext Science (VEXTF) has a Gross Margin % of 45.42% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Vext Science and its competitors. This is near median its historical median of 44.45. Over the past decade, Vext Science's Gross Margin % has ranged from 24.94 to 65.23. According to the industry distribution chart, Vext Science ranks #709 out of 938 companies in the Drug Manufacturers industry, placing it in the top 75.6%.
Is Vext Science's Gross Margin % too high?
Vext Science's current Gross Margin % of 45.42% is near median its 10-year median of 44.45. Over the past 10 years, this metric has ranged from a low of 24.94 to a high of 65.23. The Drug Manufacturers industry median Gross Margin % is 48.54. Vext Science's value of 45.42% is 6.4% below this industry median. Based on the distribution chart, Vext Science ranks #709 out of 938 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vext Science has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vext Science's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #709 out of 938 companies for Gross Margin %. This places Vext Science in the lower half of its industry. The industry median Gross Margin % is 48.54. Vext Science's value of 45.42% is 6.4% below this benchmark. Historically, Vext Science's own Gross Margin % has ranged from 24.94 to 65.23 over the past decade. While the company's 10-year median is 44.45 vs. the industry median of 48.54, Vext Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vext Science's current Gross Margin % of 45.42% is 6.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Vext Science and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current Gross Margin % is 45.42%, which is near median its own 10-year median of 44.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Based on GuruFocus' analysis, Vext Science (VEXTF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.08, compared to a current price of $0.16 — trading 85% below its estimated fair value. The current Gross Margin % is 45.42%, which is near median its 10-year median of 44.45 and 6.4% below the Drug Manufacturers industry median of 48.54. Vext Science's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Vext Science (VEXTF), the current Gross Margin % is 45.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (VEXTF) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of $0.16 is trading 85% below its estimated GF Value™ of $1.08.
GuruFocus considers Vext Science to be Possible Value Trap.
Key valuation signals for VEXTF:
Gross Margin %: 45.42% (near median its 10-year median of 44.45)
GF Value™: $1.08 vs. price of $0.16 (85% below fair value)
Industry Position: 6.4% below the Drug Manufacturers median (#709 of 938)
No single metric tells the full story. See the VEXTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
69GF Score
Get the complete analysis for VEXTF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VEXTF has been successfully added to your 
